Alterations in the p53 pathway and prognosis in advanced ovarian cancer: A multi-factorial analysis of the EORTC Gynaecological Cancer group (study 55865)

J. A. Green, E. M J J Berns, C. Coens, I. van Luijk, J. Thompson-Hehir, P. van Diest, R. H M Verheijen, M. van de Vijver, P. van Dam, G. G. Kenter, W. Tjalma, P. C. Ewing, I. Teodorovic, I. Vergote, M. E L van der Burg

Research output: Contribution to journalArticle

Abstract

Purpose: The study was designed to determine independent prognostic variables in suboptimally debulked advanced ovarian cancer patients entered in the randomised phase III study EORTC 55865. Experimental design: Retrospectively collected paraffin blocks from 169 patients with stages IIb-IV epithelial ovarian cancer, taken at primary debulking surgery, were analysed. All patients were treated with cyclophosphamide and cisplatin (CP), and followed up for a median of 10 years. Expression of p53, bcl-2, P21, Ki-67 and HER-2 status was assessed by immunohistochemistry (IHC). Results: Expression of p21, a downstream effector of the p53 gene, was found to be a favourable prognostic factor for survival (HR 0.58, CI 0.36-0.94, p = 0.025) in addition to FIGO stage (HR 1.54, CI 1.08-2.21, p = <0.02). For progression free survival (PFS), both p21 (HR 0.52) and Ki-67 (HR 0.6) were significant factors. Conclusion: P21 overexpression is a positive prognostic factor for survival and PFS in advanced ovarian carcinoma with residual lesions of more than 1 cm.

Original languageEnglish (US)
Pages (from-to)2539-2548
Number of pages10
JournalEuropean Journal of Cancer
Volume42
Issue number15
DOIs
StatePublished - Oct 2006
Externally publishedYes

Fingerprint

Ovarian Neoplasms
Disease-Free Survival
Neoplasms
Survival
p53 Genes
Paraffin
Cyclophosphamide
Cisplatin
Research Design
Immunohistochemistry
Carcinoma
Ovarian epithelial cancer

Keywords

  • Bcl-2
  • DNA ploidy
  • Immunohistochemistry
  • MIB-1
  • Morphometry
  • P21
  • P53
  • Prognosis
  • Suboptimally debulked advanced ovarian cancer

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Green, J. A., Berns, E. M. J. J., Coens, C., van Luijk, I., Thompson-Hehir, J., van Diest, P., ... van der Burg, M. E. L. (2006). Alterations in the p53 pathway and prognosis in advanced ovarian cancer: A multi-factorial analysis of the EORTC Gynaecological Cancer group (study 55865). European Journal of Cancer, 42(15), 2539-2548. https://doi.org/10.1016/j.ejca.2006.06.015

Alterations in the p53 pathway and prognosis in advanced ovarian cancer : A multi-factorial analysis of the EORTC Gynaecological Cancer group (study 55865). / Green, J. A.; Berns, E. M J J; Coens, C.; van Luijk, I.; Thompson-Hehir, J.; van Diest, P.; Verheijen, R. H M; van de Vijver, M.; van Dam, P.; Kenter, G. G.; Tjalma, W.; Ewing, P. C.; Teodorovic, I.; Vergote, I.; van der Burg, M. E L.

In: European Journal of Cancer, Vol. 42, No. 15, 10.2006, p. 2539-2548.

Research output: Contribution to journalArticle

Green, JA, Berns, EMJJ, Coens, C, van Luijk, I, Thompson-Hehir, J, van Diest, P, Verheijen, RHM, van de Vijver, M, van Dam, P, Kenter, GG, Tjalma, W, Ewing, PC, Teodorovic, I, Vergote, I & van der Burg, MEL 2006, 'Alterations in the p53 pathway and prognosis in advanced ovarian cancer: A multi-factorial analysis of the EORTC Gynaecological Cancer group (study 55865)', European Journal of Cancer, vol. 42, no. 15, pp. 2539-2548. https://doi.org/10.1016/j.ejca.2006.06.015
Green, J. A. ; Berns, E. M J J ; Coens, C. ; van Luijk, I. ; Thompson-Hehir, J. ; van Diest, P. ; Verheijen, R. H M ; van de Vijver, M. ; van Dam, P. ; Kenter, G. G. ; Tjalma, W. ; Ewing, P. C. ; Teodorovic, I. ; Vergote, I. ; van der Burg, M. E L. / Alterations in the p53 pathway and prognosis in advanced ovarian cancer : A multi-factorial analysis of the EORTC Gynaecological Cancer group (study 55865). In: European Journal of Cancer. 2006 ; Vol. 42, No. 15. pp. 2539-2548.
@article{332e338568ce4f319b95bded3fa9f1ab,
title = "Alterations in the p53 pathway and prognosis in advanced ovarian cancer: A multi-factorial analysis of the EORTC Gynaecological Cancer group (study 55865)",
abstract = "Purpose: The study was designed to determine independent prognostic variables in suboptimally debulked advanced ovarian cancer patients entered in the randomised phase III study EORTC 55865. Experimental design: Retrospectively collected paraffin blocks from 169 patients with stages IIb-IV epithelial ovarian cancer, taken at primary debulking surgery, were analysed. All patients were treated with cyclophosphamide and cisplatin (CP), and followed up for a median of 10 years. Expression of p53, bcl-2, P21, Ki-67 and HER-2 status was assessed by immunohistochemistry (IHC). Results: Expression of p21, a downstream effector of the p53 gene, was found to be a favourable prognostic factor for survival (HR 0.58, CI 0.36-0.94, p = 0.025) in addition to FIGO stage (HR 1.54, CI 1.08-2.21, p = <0.02). For progression free survival (PFS), both p21 (HR 0.52) and Ki-67 (HR 0.6) were significant factors. Conclusion: P21 overexpression is a positive prognostic factor for survival and PFS in advanced ovarian carcinoma with residual lesions of more than 1 cm.",
keywords = "Bcl-2, DNA ploidy, Immunohistochemistry, MIB-1, Morphometry, P21, P53, Prognosis, Suboptimally debulked advanced ovarian cancer",
author = "Green, {J. A.} and Berns, {E. M J J} and C. Coens and {van Luijk}, I. and J. Thompson-Hehir and {van Diest}, P. and Verheijen, {R. H M} and {van de Vijver}, M. and {van Dam}, P. and Kenter, {G. G.} and W. Tjalma and Ewing, {P. C.} and I. Teodorovic and I. Vergote and {van der Burg}, {M. E L}",
year = "2006",
month = "10",
doi = "10.1016/j.ejca.2006.06.015",
language = "English (US)",
volume = "42",
pages = "2539--2548",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Limited",
number = "15",

}

TY - JOUR

T1 - Alterations in the p53 pathway and prognosis in advanced ovarian cancer

T2 - A multi-factorial analysis of the EORTC Gynaecological Cancer group (study 55865)

AU - Green, J. A.

AU - Berns, E. M J J

AU - Coens, C.

AU - van Luijk, I.

AU - Thompson-Hehir, J.

AU - van Diest, P.

AU - Verheijen, R. H M

AU - van de Vijver, M.

AU - van Dam, P.

AU - Kenter, G. G.

AU - Tjalma, W.

AU - Ewing, P. C.

AU - Teodorovic, I.

AU - Vergote, I.

AU - van der Burg, M. E L

PY - 2006/10

Y1 - 2006/10

N2 - Purpose: The study was designed to determine independent prognostic variables in suboptimally debulked advanced ovarian cancer patients entered in the randomised phase III study EORTC 55865. Experimental design: Retrospectively collected paraffin blocks from 169 patients with stages IIb-IV epithelial ovarian cancer, taken at primary debulking surgery, were analysed. All patients were treated with cyclophosphamide and cisplatin (CP), and followed up for a median of 10 years. Expression of p53, bcl-2, P21, Ki-67 and HER-2 status was assessed by immunohistochemistry (IHC). Results: Expression of p21, a downstream effector of the p53 gene, was found to be a favourable prognostic factor for survival (HR 0.58, CI 0.36-0.94, p = 0.025) in addition to FIGO stage (HR 1.54, CI 1.08-2.21, p = <0.02). For progression free survival (PFS), both p21 (HR 0.52) and Ki-67 (HR 0.6) were significant factors. Conclusion: P21 overexpression is a positive prognostic factor for survival and PFS in advanced ovarian carcinoma with residual lesions of more than 1 cm.

AB - Purpose: The study was designed to determine independent prognostic variables in suboptimally debulked advanced ovarian cancer patients entered in the randomised phase III study EORTC 55865. Experimental design: Retrospectively collected paraffin blocks from 169 patients with stages IIb-IV epithelial ovarian cancer, taken at primary debulking surgery, were analysed. All patients were treated with cyclophosphamide and cisplatin (CP), and followed up for a median of 10 years. Expression of p53, bcl-2, P21, Ki-67 and HER-2 status was assessed by immunohistochemistry (IHC). Results: Expression of p21, a downstream effector of the p53 gene, was found to be a favourable prognostic factor for survival (HR 0.58, CI 0.36-0.94, p = 0.025) in addition to FIGO stage (HR 1.54, CI 1.08-2.21, p = <0.02). For progression free survival (PFS), both p21 (HR 0.52) and Ki-67 (HR 0.6) were significant factors. Conclusion: P21 overexpression is a positive prognostic factor for survival and PFS in advanced ovarian carcinoma with residual lesions of more than 1 cm.

KW - Bcl-2

KW - DNA ploidy

KW - Immunohistochemistry

KW - MIB-1

KW - Morphometry

KW - P21

KW - P53

KW - Prognosis

KW - Suboptimally debulked advanced ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=33748959684&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748959684&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2006.06.015

DO - 10.1016/j.ejca.2006.06.015

M3 - Article

C2 - 16965910

AN - SCOPUS:33748959684

VL - 42

SP - 2539

EP - 2548

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 15

ER -